New research demonstrates the ability of ResistAid, Lonza’s all-natural arabinogalactan-based immune ingredient, to increase the antibody response of healthy volunteers to the 23-valent pneumococcal (pneumonia) vaccine. The study was conducted in collaboration with Medicus Research LLC and published in the August issue of Nutrition Journal.
This randomized, double-blind, placebo-controlled, parallel group study demonstrate the ability of ResistAid to selectively enhance the antibody response to the pneumococcal vaccine, according to researchers.
The study showed vaccinated volunteers who received ResistAid for 30 days prior to the vaccine and up to Day 72 demonstrated significantly higher pneumococcal IgG levels in two antibodies subtypes (18C and 23F) at both Day 51 and at Day 72 compared to the placebo group. These same subtypes (18C and 23F) also demonstrated statistically significant change scores from baseline in the ResistAid group at Day 51 and at Day 72. For further information: www.lonza.com